Antibody Binders for Bispecifics, Multispecifics & TCEs

Bispecific antibodies (bsAbs), multispecific antibodies (msAbs), and T‑cell engagers (TCEs) have become a central pillar of next‑generation biologics, transitioning from niche therapeutic modalities into mainstream clinical and commercial pipelines.

Format and engineering diversity: Flexible scaffolds, Fc‑silencing or Fc‑enhanced formats, tumor‑selective antibodies, and bispecific antibody–drug conjugates (ADCs) are being deployed to enhance specificity, lower toxicity, and expand the therapeutic window.
Dual‑ and multi‑target logic: Targeting two antigens or two epitopes is being used to boost selectivity, overcome resistance mechanisms, and maintain T‑cell functionality.

Developability and manufacturability: focus on improved stability, higher expression yields, and lower aggregation to enable large‑scale development of complex multispecific formats.

Our Antibody Discovery Studio delivers high-affinity binders tailored for complex formats like bispecifics, multispecifics, and T-cell engagers (TCEs).

Leveraging AI-powered dual-display workflows and synthetic libraries of billions of human antibodies, we address the unique challenges of multi-domain engineering.

Why choose LiteMab© Antibody Discovery Studio?

Versatile target compatibility: Excels with any targets from soluble to membrane proteins—ideal for TCE and multispecifics designs requiring precise epitope targeting.

Plug & Play format: scFv format enables rapid assembly and flexible combination of binding domains, significantly streamlining the design and optimization of bispecifics, multispecific antibodies with improved scalability and reduced development timelines.

Integrated Discovery & Maturation: Seamlessly combines binder discovery / affinity maturation and functional screening, ensuring developability for bispecific and multispecific formats.
pH-Sensitive & Conditional Activity: Specializes in tumor-selective binders that enhance specificity, PK, and reduce off-target effects in ADCs, multispecifics, and TCEs.

This holistic approach minimizes risks in competitive programs, incorporating target knowledge, functionality, pharmacology, and manufacturability from the start.

Proven Workflow

Our streamlined antibody discovery workflow integrates cutting‑edge synthetic libraries and AI‑powered dual display screening technologies to rapidly deliver high‑quality, fully human therapeutic candidates. From target to validated lead, we combine robust selection, in‑depth characterization, and functional validation into a single, efficient process tailored for complex biologics development.

Fully human antibody libraries screening: High-throughput dual-display selection against single or dual epitopes.
Functional hit validation: Fir for purpose functional assays
Tumor-selective binders: Multispecific formatting with pH-sensitive features for superior therapeutic windows and reduced toxicity (LiteMab© Sense, LiteMab© Neo Sense).
Developability Assessment: Early prediction of stability, expression, and immunogenicity.

Our studio accelerates timelines while maximizing success rates for next-generation immunotherapies.

Benefit of an end-to-end solution for the discovery and development of complex biologics

Mabqi and Abzena unite their expertise to provide a seamless end-to-end solution for antibody discovery and development :

Combined scientific know-how and technical support for clients
Cutting-edge scientific and technical capabilities for complex biologics
Science & results-driven partnership
Clear, easy-to-understand mode of operation of the partnership

Antibody Binders for Bispecifics, Multispecifics & TCEs

Why choose LiteMab© Antibody Discovery Studio?

Proven Workflow

Benefit of an end-to-end solution for the discovery and development of complex biologics

Ready to advance your bispecific, multispecific, or TCE programs?